pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cardiology · news · pharmadog
← back to Cardiology
News · Cardiology
793
stories
9h
Anthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’
fiercebiotech
9h
Novartis projects slowed growth, pins hopes on billions in pipeline potential
biospace
10h
nChroma halves workforce, BioXcel lets execs go
biospace
14h
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
stat
16h
Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins
stat
21h
Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment
fiercebiotech
1d
STAT+: Influential preventive services panel to meet for first time in more than a year
stat
1d
CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
biospace
1d
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
2d
GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
endpoints
2d
Roche breast cancer pill cleared by FDA
biopharma dive
2d
STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
stat
2d
Medtronic pays $380M-plus for Contego Medical buyout
fiercebiotech
3d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
3d
BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
biospace
4d
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
stat
6d
New addiction society guidance on medetomidine’s brutal withdrawal
stat
6d
Cellectis could cut 70% of workforce in shift to in vivo therapies
biospace
6d
STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
stat
6d
Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3
endpoints
6d
Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filing
endpoints
6d
STAT+: HHS plans funding for research into ibogaine for PTSD
stat
6d
Opinion: New organ donation rules are unfair to families
stat
6d
Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
biospace
6d
The future of heart drug research in the wake of study setbacks
stat
6d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
6d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
6d
Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
fiercebiotech
7d
Webinar: Optimizing Cell Therapy Manufacturing Efficiency with Cryopreserved Cells
biospace
← prev
page 1 of 27
next →